Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6810571 | 0.93 | CHRNB2 (0.34) | — | |
| SCHEMBL185803 | 0.75 | HPGD (0.39) | CYP2C19HIF1A | |
| SCHEMBL15415530 | 0.74 | ALOX5 (0.46) | — | |
| SCHEMBL7397869 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL5303475 | 0.73 | — | — | |
| SCHEMBL918905 | 0.73 | CHKA (0.39) | CYP2C19HIF1A | |
| SCHEMBL526372 | 0.73 | PLD1 (0.44) | — | |
| SCHEMBL15416277 | 0.70 | PLD1 (0.39) | — | |
| SCHEMBL2067060 | 0.70 | CHKA (0.34) | CYP2C19 | |
| SCHEMBL28080101 | 0.68 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| EP-3436456-B1 | FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3436460-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3201196-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3436458-B1 | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-06-02 | — | — | EP | disclosed |
| US-20210155637-A1 | Fused Pentacyclic Imidazole Derivatives | SANOFI (FR) | 2021-05-27 | — | — | US | disclosed |
| US-10953019-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2021-03-23 | — | — | US | disclosed |
| US-10906919-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2021-02-02 | — | — | US | disclosed |
| US-10793578-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2020-10-06 | — | — | US | disclosed |
| US-10766906-B2 | Fused hexacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2020-09-08 | — | — | US | disclosed |
| WO-2015086508-A1 | BENZOTRIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086498-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086523-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2872511-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2858983-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB Biopharma SPRL (BE) | 2015-04-15 | — | — | EP | disclosed |
| WO-2014009296-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013186229-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB PHARMA S.A. (BE) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | CYP2C19 1792/4885HIF1A 771/4885 |
| US-10906919-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | CYP2C19 499/4885HIF1A 1959/4885 |
| US-20210155637-A1 | Fused Pentacyclic Imidazole Derivatives | TNF, NFKBIA, TNFRSF1A | CYP2C19 499/4885HIF1A 1959/4885 |
| US-10953019-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | CYP2C19 3155/4885HIF1A 2178/4885 |
| US-10766906-B2 | Fused hexacyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | CYP2C19 834/4885HIF1A 2493/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | CYP2C19 499/4885HIF1A 1959/4885 |
| US-10793578-B2 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | CYP2C19 1191/4885HIF1A 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.